Aldakkour Jamie Lee, Newman-Caro Alvin Boyd, Bardan Usama, Gonzalez-Montalvo Hector, Ramamurthy Guruswamy
HCA Florida Blake Hospital, Bradenton, Florida.
HCA Healthc J Med. 2025 Apr 1;6(2):163-166. doi: 10.36518/2689-0216.1512. eCollection 2025.
Guillain-Barré Syndrome (GBS) is an acute autoimmune polyneuropathy. Cases of GBS have been reported following administration of the vaccines for swine influenza, seasonal influenza, hemagglutinin type 1 and neuraminidase type 1, and meningococcal disease. Despite these links, a causal relationship has not been confirmed.
We present a case of a 70-year-old woman who presented with progressive bilateral ascending weakness and numbness and reported receiving the first dose of the Moderna COVID-19 vaccine 2 weeks prior to presentation.
At the time of writing, this is the first reported case of GBS following the Moderna Spikevax COVID-19 vaccine. While a temporal link does not confirm causation, vigilance for GBS symptoms in recently vaccinated patients is crucial. Early recognition enables timely treatment, preventing severe complications like respiratory failure. However, the public health benefits of vaccination far outweigh the risks, as it remains the most effective tool in preventing severe disease.
吉兰-巴雷综合征（GBS）是一种急性自身免疫性多发性神经病。在接种猪流感疫苗、季节性流感疫苗、1型血凝素和1型神经氨酸酶疫苗以及脑膜炎球菌病疫苗后，均有GBS病例报告。尽管存在这些关联，但因果关系尚未得到证实。
我们报告一例70岁女性病例，该患者出现进行性双侧上行性无力和麻木，并报告在出现症状前2周接种了第一剂莫德纳新冠疫苗。
在撰写本文时，这是首例接种莫德纳新冠疫苗后发生GBS的报告病例。虽然时间上的关联不能证实因果关系，但对近期接种疫苗患者的GBS症状保持警惕至关重要。早期识别有助于及时治疗，预防呼吸衰竭等严重并发症。然而，疫苗接种对公共卫生的益处远远超过风险，因为它仍然是预防严重疾病的最有效工具。
